



## **Invitation to Investor Briefing**

**7 March 2018: Actinogen Medical (ASX: ACW)** invites all shareholders and the wider investment community to a series of open Investor Briefings that will take place around Australia, during March.

The Company will provide an overview of the business and an update on XanADu, its Phase II clinical trial of Xanamem for the treatment of Alzheimer's disease.

The briefings will take place at the following locations and times:

**Perth: Monday 19<sup>th</sup> March, 4:30pm – 5:30pm**

*Steve's Hotel in the Cellar, 30 The Avenue, Nedlands, Perth*

**Adelaide: Tuesday 20<sup>th</sup> March, 4:30pm – 5:30pm**

*Baker Young Offices, Board Room, Level 6, 121 King William St, Adelaide*

**Melbourne: Wednesday 21<sup>st</sup> March, 4:30pm – 5:30pm**

*Mantra on Russell, Flinders Conference Room, 222 Russell Street, Melbourne*

**Sydney: Thursday 22<sup>nd</sup> March, 5pm – 6pm**

*The Royal Exchange, Main Dining Room and Bar, 1 Gresham Street, Sydney*

The briefings will be followed by a drinks service and the opportunity to talk with Actinogen management.

For registration and catering purposes, ***please RSVP and indicate which location you will be attending to:***

Therese Russell  
Actinogen Medical  
[therese.russell@actinogen.com.au](mailto:therese.russell@actinogen.com.au)

**ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### **Media Enquires**

Zena Chamas  
Media & Capital Partners  
M: +61 434 153 055  
E: [zena.chamas@mcpartners.com.au](mailto:zena.chamas@mcpartners.com.au)

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**